Oncolytics Biotech unveils design for pancreatic cancer registration trial
PositiveFinancial Markets

Oncolytics Biotech has announced the design for a registration trial aimed at treating pancreatic cancer, a disease known for its challenging prognosis. This development is significant as it could lead to new treatment options for patients suffering from this aggressive cancer, potentially improving survival rates and quality of life. The trial's design reflects a commitment to advancing cancer research and addressing unmet medical needs.
— Curated by the World Pulse Now AI Editorial System